Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Amneal Pharmaceuticals, Inc.AMRX · healthcare | |
|---|---|
| Grade |  Cmiddle fifth of 371 graded peers; percentile 48.4, sampling error 2.5 points; lower is stronger |
| Rank | 180 of 371 |
| Profitability | Bpercentile 35.9 |
| Solvency | Dpercentile 75.7 |
| Growth and financing | Bpercentile 30.5 |
| Reliability | 0.94 AUCfailure model, filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| Peer failure rate | 0.52% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | over $2.67B assetstotal assets $3.7B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none activenot computable: distress |
| Inputs computable | 11 of 14 |
| Graded from | filings received through Feb 27, 2026224 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $19.652026-10-08; market equity $6.3B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 27, 2026; the document on sec.gov.
Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 35.9 | |||||||
| Gross profitability | 30.3% | [1,3] | 32.2% | 49.3 | 372 | 2025-12-31 | |
| Return on invested capital | 16.5% | [4-12] | 9.3% | 28.8 | 74 | 2025-12-31 | |
| Accruals ratio | (7.5%) | [1,13-15] | (6.6%) | 52.2 | 811 | 2025-12-31 | |
| Gross margin stability, five years | 1.0 pts | [2-3,16-23] | 2.8 pts | 13.2 | 243 | 2025-12-31 | |
| Solvency, sleeve percentile 75.7 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-06-30 | |||||||
| Altman Z double-prime | not computable | (0.31) | |||||
| required facts have no common fiscal period end | |||||||
| Net debt to EBITDA | 5.07x | [4,7,9,24] | 1.82x | 82.4 | 75 | 2025-12-31 | |
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 2.17x | [25-26] | 2.96x | 69.0 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 30.5 | |||||||
| Revenue growth, three-year compound | 10.9% | [2,17,19,21] | 10.0% | 47.8 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | 143.5% | [14,27-33] | 10.9% | 2.1 | 96 | 2025-12-31 | |
| Reinvestment rate | 161.3% | [4-6,24-27,34-35] | 37.1% | 19.4 | 104 | 2025-12-31 | |
| Asset growth, three years | (1.1%) | [1,15,36-37] | 2.1% | 53.6 | 704 | 2025-12-31 | |
| Net share issuance, one year | 1.5% | [38-39] | 2.5% | 29.4 | 634 | 2026-02-13 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite -0.060; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 175 | ClearPoint Neuro, Inc. (CLPT) ClearPoint Neuro, Inc. (CLPT) Cmiddle fifth; percentile 47.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $320.0M; last close $10.47 No active warnings; 8 of 14 inputs | 47.0 | C | |
| 176 | Anika Therapeutics, Inc. (ANIK) Anika Therapeutics, Inc. (ANIK) Cmiddle fifth; percentile 47.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $257.4M; last close $19.20 Warnings: fortress balance sheet; 7 of 14 inputs | 47.3 | C | fortress balance sheet |
| 177 | Davita Inc. (DVA) Davita Inc. (DVA) Cmiddle fifth; percentile 47.6 NYSE · Services-Misc Health & Allied Services, NEC market equity $11.3B; last close $177.21 No active warnings; 12 of 14 inputs | 47.6 | C | |
| 178 | Kymera Therapeutics, Inc. (KYMR) Kymera Therapeutics, Inc. (KYMR) Cmiddle fifth; percentile 47.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.1B; last close $109.34 Warnings: dilution; 7 of 14 inputs | 47.8 | C | dilution |
| 179 | Scynexis Inc. (SCYX) Scynexis Inc. (SCYX) Cmiddle fifth; percentile 48.1 Nasdaq · Pharmaceutical Preparations market equity $42.0M; last close $4.19 Warnings: fortress balance sheet; 7 of 14 inputs | 48.1 | C | fortress balance sheet |
| 180 | Amneal Pharmaceuticals, Inc. (AMRX) Amneal Pharmaceuticals, Inc. (AMRX) Cmiddle fifth; percentile 48.4 Nasdaq · Pharmaceutical Preparations market equity $6.3B; last close $19.65 No active warnings; 11 of 14 inputs | 48.4 | C | |
| 181 | Macrogenics Inc. (MGNX) Macrogenics Inc. (MGNX) Cmiddle fifth; percentile 48.6 Nasdaq · Pharmaceutical Preparations market equity $226.1M; last close $3.54 No active warnings; 8 of 14 inputs | 48.6 | C | |
| 182 | Savara Inc. (SVRA) Savara Inc. (SVRA) Cmiddle fifth; percentile 48.9 Nasdaq · Pharmaceutical Preparations market equity $992.4M; last close $4.84 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | 48.9 | C | short runway, fortress balance sheet |
| 183 | Biodesix Inc. (BDSX) Biodesix Inc. (BDSX) Cmiddle fifth; percentile 49.2 Nasdaq · Services-Medical Laboratories market equity $270.4M; last close $25.36 Warnings: dilution; 7 of 14 inputs | 49.2 | C | dilution |
| 184 | Evolus, Inc. (EOLS) Evolus, Inc. (EOLS) Cmiddle fifth; percentile 49.5 Nasdaq · Pharmaceutical Preparations market equity $515.2M; last close $7.80 No active warnings; 8 of 14 inputs | 49.5 | C | |
| 185 | Neogen Corp. (NEOG) Neogen Corp. (NEOG) Cmiddle fifth; percentile 49.7 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $2.6B; last close $11.71 Warnings: late filer; 9 of 14 inputs | 49.7 | C | late filer |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | B | 30.2 | 2204 |
| sector peers, equal sleeves (the grade) | C | 48.4 | 371 |
| same exchange, equal sleeves | B | 35.7 | 1219 |
| sector peers, equal inputs | B | 26.8 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 74.5% | 8.0% | 84 | hotter than 84 of 100 peers |
| Distance from 52-week high | (4.1%) | (31.4%) | 94 | closer to its high than 94 of 100 peers |
| EBIT to enterprise value | 4.5% | (1.5%) | 74 | pricier than 26 of 100 peers |
| Free cash flow yield | 4.3% | (1.0%) | 77 | pricier than 23 of 100 peers |
| Book value to price | 0.01 | 0.28 | 12 | pricier than 88 of 100 peers |
| Sales to price | 0.48 | 0.31 | 65 | pricier than 35 of 100 peers |
| Composite equity issuance, five years | not computable | 20.3% | a share count from five years earlier is required | |
| Relative strength against the sector, log excess return | 0.34 | (0.14) | 84 | ahead of 84 of 100 peers |
Inputs: market equity $6.3B; EBIT $394.1M; free cash flow $269.9M; book equity $33.0M; sales $3.0B; debt $2.6B; cash $127.6M[40].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: 7 of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | 2.1% | ✓ pass[13,15] |
| Operating cash flow above zero | $340.0M | ✓ pass[14] |
| Return on assets improved | 4.2 pts | ✓ pass[13,15,36,41] |
| Operating cash flow exceeds net income | $267.9M | ✓ pass[13-14] |
| Long-term leverage fell | 9.5 pts | ✗ fail[1,15,36,42-43] |
| Current ratio improved | 76.2 pts | ✓ pass[25-26,34-35] |
| No new shares issued | 1.5% | ✗ fail[38-39] |
| Gross margin improved | 0.4 pts | ✓ pass[2-3,16-17] |
| Asset turnover improved | 5.8 pts | ✓ pass[2,15,17,36] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $127.6M[44] |
| Operating cash flow, four quarters | $200.8M[14,44-48] |
| Months of runway | not finite |
| trailing operating cash flow is nonnegative, so runway is not finite | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 64 |
| 10-Q received Aug 6, 2026 | |
| Median daily dollar volume | $36.8M |
| 63 sessions | |
| Days since newest grade input | 224 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $3.7B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $3.0B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 3 | gross profit | us-gaap:GrossProfit | $1.1B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 4 | operating income | us-gaap:OperatingIncomeLoss | $394.1M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $139.2M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | $11.3M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 7 | total debt | us-gaap:LongTermDebt | $2.6B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 8 | book equity | us-gaap:StockholdersEquity | -$70.8M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $282.0M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 10 | total debt | us-gaap:LongTermDebt | $2.4B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | -$109.3M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $110.6M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 13 | net income | us-gaap:NetIncomeLoss | $72.1M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $340.0M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $3.5B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 16 | gross profit | us-gaap:GrossProfit | $1.0B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.8B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 18 | gross profit | us-gaap:GrossProfit | $820.6M | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.4B | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 20 | gross profit | us-gaap:GrossProfit | $784.7M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.2B | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 22 | gross profit | us-gaap:GrossProfit | $769.0M | 2021-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.1B | 2021-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 24 | depreciation amortization | us-gaap:Depreciation | $57.3M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 25 | current assets | us-gaap:AssetsCurrent | $1.9B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $881.6M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $70.1M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $295.1M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $51.9M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $345.6M | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $43.2M | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $65.1M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $46.4M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 34 | current assets | us-gaap:AssetsCurrent | $1.6B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 35 | current liabilities | us-gaap:LiabilitiesCurrent | $1.1B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 36 | assets | us-gaap:Assets | $3.5B | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 37 | assets | us-gaap:Assets | $3.8B | 2022-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 314,629,101 | 2026-02-13 | 2026-02-27 | 10-K | filing · viewer · series |
| 39 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 309,966,341 | 2025-02-14 | 2025-02-28 | 10-K | filing · viewer · series |
| 40 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 319,353,919 | 2026-07-31 | 2026-08-06 | 10-Q | filing · viewer · series |
| 41 | net income | us-gaap:ProfitLoss | -$73.9M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 42 | long term debt | us-gaap:LongTermDebtNoncurrent | $2.6B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 43 | long term debt | us-gaap:LongTermDebtNoncurrent | $2.2B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 44 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $127.6M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 45 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$48.0M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 46 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$26.7M | 2026-03-31 | 2026-05-07 | 10-Q | filing · viewer · series |
| 47 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $209.7M | 2025-09-30 | 2025-11-06 | 10-Q | filing · viewer · series |
| 48 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $91.2M | 2025-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 48.4 is 8.4 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
